All provinces, autonomous regions, municipalities directly under the Central Government and Xinjiang Production and Construction Corps Health and Health Commission, Development and Reform Commission, Industry and Information Technology Department, Finance Department (Bureau), Department of Ecology and Environment (Bureau), Commerce Department, State-owned Assets Supervision and Administration Commission, Market Supervision Bureau (Department, Commission), Health Insurance Bureau, Chinese Medicine Bureau, Drug Administration, and relevant units of the military.

In accordance with the requirements of the Opinions of the General Office of the State Council on Further Improving the Work of Shortage Drug Supply and Price Stabilization ([2019] No. 47), the lead unit (National Health and Wellness Commission) of the National Shortage Drug Supply Security Work Consultation and Linkage Mechanism (hereinafter referred to as the National Linkage Mechanism) has formulated the National Shortage Drug List Management Measures (for Trial Implementation) (Annex 1) in consultation with all member units. It is hereby issued to you, please follow the implementation. Drugs for which the provincial linkage mechanism is unable to effectively solve the shortage problem within a certain period of time through direct listing, independent filing and drug stockpiling, etc. will be reported to the national linkage mechanism lead unit through the Shortage Drug Information Reporting Form (Annex 2).

Tel: 010-68792630, 68791452

Other information